A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator.
The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g.
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb.
A serum protein which is important in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY. This enzyme cleaves the COMPLEMENT C3B-bound COMPLEMENT FACTOR B to form C3bBb which is ALTERNATIVE PATHWAY C3 CONVERTASE.

In vitro analysis of complement-dependent HIV-1 cell infection using a model system. (1/80)

Previous studies based on the use of human serum as a source of C have provided evidence for the C-dependent enhancement of cell infection by HIV-1. The present study was undertaken to distinguish C from other serum factors and to identify the proteins and the mechanisms involved in C-dependent cell infection by HIV-1. The classical C activation pathway was reconstituted from the proteins C1q, C1r, C1s, C4, C2, C3, factor H, and factor I; each were purified to homogeneity. A mixture of these proteins at physiological concentrations was shown to reproduce the ability of normal human serum to enhance the infection of MT2 cells by HIV-1 at low doses of virus. This enhancing effect was abolished when heat-inactivated serum and C2- or C3-depleted serum were used, and was restored upon addition of the corresponding purified proteins. A mixture of two synthetic peptides corresponding to positions 10-15 and 90-97 of human C receptor type 2 (CD21) as well as soluble CD4 both inhibited the C-dependent infection process. These data provide unambiguous evidence that HIV-1 triggers a direct activation of the classical C pathway in vitro and thereby facilitates the infection of MT2 cells at low doses of virus. These findings are consistent with a mechanism involving increased interaction between the virus opsonized by C3b-derived fragment(s) and the CD21 cell receptors and subsequent virus entry through CD4 receptors.  (+info)

A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function. (2/80)

C4b-binding protein (C4BP) is a regulator of the classical complement pathway, acting as a cofactor to factor I in the degradation of C4b. Computer modeling and structural analysis predicted a cluster of positively charged amino acids at the interface between complement control protein modules 1 and 2 of the C4BP alpha-chain to be involved in C4b binding. Three C4BP mutants, R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q, were expressed and assayed for their ability to bind C4b and to function as factor I cofactors. The apparent affinities of R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q for immobilized C4b were 15-, 50-, and 140-fold lower, respectively, than that of recombinant wild type C4BP. The C4b binding site demonstrated herein was also found to be a specific heparin binding site. In C4b degradation, the mutants demonstrated decreased ability to serve as factor I cofactors. In particular, the R39Q/R64Q/R66Q mutant was inefficient as cofactor for cleavage of the Arg937-Thr938 peptide bond in C4b. In contrast, the factor I mediated cleavage of Arg1317-Asn1318 bond was less affected by the C4BP mutations. In conclusion, we identify a cluster of amino acids that is part of a C4b binding site involved in the regulation of the complement system.  (+info)

Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). (3/80)

In humans, host cells are protected from homologous complement by membrane proteins encoded in the regulators of complement activation (RCA) gene cluster. These include complement receptor 1 (CR1), decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46). In mouse and rat a single membrane inhibitor, Crry, appeared to perform the functions of both DAF and MCP and was proposed to be the functional analogue of both. Recently, however, murine homologues of DAF and MCP have been identified, prompting a search for the rat counterparts. We have described the identification of rat DAF and here describe the cloning of rat MCP from cDNA and genomic libraries, using a probe based on the mouse MCP cDNA sequence. The domain structure for rat MCP was identical to that of mouse MCP with four short consensus repeats (SCRs) followed by a STP domain, transmembrane segment and cytoplasmic tail. Overall identity of rat and mouse MCP was 77% at the amino acid level and 88% at the nucleotide level. Northern blot analysis from a range of tissues indicated that high-level expression was limited to the testis, although expression in other tissues was detected using reverse transcription-polymerase chain reaction. Rat MCP mRNA localized to Sertoli cells and spermatogonia in seminiferous tubules by in situ hybridization, but was absent in mature sperm. In cofactor assays utilizing human factor I, a recombinant soluble form of rat MCP catalysed cleavage of human C3ma.  (+info)

Function of the factor I modules (FIMS) of human complement component C6. (4/80)

In order to elucidate the function of complement component C6, truncated C6 molecules were expressed recombinantly. These were either deleted of the factor I modules (FIMs) (C6des-748-913) or both complement control protein (CCP) modules and FIMs (C6des-611-913). C6des-748-913 exhibited approximately 60-70% of the hemolytic activity of full-length C6 when assayed for Alternative Pathway activity, but when measured for the Classical Pathway, C6des-748-914 was only 4-6% as effective as C6. The activity difference between C6 and C6des-748-913 for the two complement pathways can be explained by a greater stability of newly formed metastable C5b* when produced by the Alternative Pathway compared with that made by the Classical Pathway. The half-lives of metastable C5b* and the decay of (125)I-C5b measured from cells used to activate the Alternative Pathway were found to be about 5-12-fold longer than those same parameters derived from cells that had activated the Classical Pathway. (125)I-C5 binds reversibly to C6 in an ionic strength-dependent fashion, but (125)I-C5 binds only weakly to C6des-FIMs and not at all to C6des-CCP/FIMs. Therefore, although the FIMs are not required absolutely for C6 activity, these modules promote interaction of C6 with C5 enabling a more efficient bimolecular coupling ultimately leading to the formation of the C5b-6 complex.  (+info)

Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells. (5/80)

Factor I (FI) is a regulatory serine protease of the complement system which cleaves three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. The human protein and the recently characterized mouse factor I are heterodimers of about 88,000 MW which consist of a non-catalytic heavy chain of 50,000 MW which is linked to a catalytic light chain of 38,000 MW by a disulphide bond. For the screening of a rat liver cDNA library we used a hybridization probe produced by polymerase chain reaction (PCR) using degenerated primers which corresponded to conserved parts of the human and the murine factor I nucleotide sequences. One of the identified sequences, which had a length of 2243 base pairs (bp), contained the complete coding region and the whole 3' untranslated region. The length of the coding region in rat consisted of 1812 bp followed by a 3' untranslated region of 207 bp including the polyadenylation signal and the beginning of the poly A tail. Comparison of the rat cDNA-derived coding sequence revealed identities of 87% to the mouse and of 78% to the human FI nucleotide sequence. The translation product of rat FI mRNA was 604 amino acid residues (aa) in length with an identity of 85% to the mouse (603 aa) and 69% to the human protein (583 aa). The comparison of the molecular mass predicted by the primary structure and derived from rat FI isolated from rat serum as detected in immunoblot analyses suggested a glycosylation of more than 20% of the total mass of the FI protein. Expression studies using reverse transcription (RT)-PCR assays indicated that FI-specific mRNA could neither be identified in B cells, nor in T cells, monocytes or granulocytes from rat and human peripheral blood nor in rat peritoneal macrophages. These data were in agreement with the results of RT-PCR obtained with several human lymphoma cell lines (Jurkat, MOLT-4, HUT102, Wil 2-NS, Ramos, Raji, U937) all of which were devoid of FI-specific mRNA. In accord with our data from two rat hepatoma cell lines (FAO and H4IIE) and one from man (HepG2) only isolated rat hepatocytes (HC) but neither Kupffer cells (KC), hepatic stellate cells (HSC; Ito cells) nor sinusoidal endothelial cells (SEC) expressed FI-specific mRNA. FI mRNA was also detected in human umbilical vein endothelial cells (HUVEC) and in the uterus and small intestine of the rat. Spleen and lymph nodes did not contain any detectable FI-specific mRNA.  (+info)

Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells. (6/80)

The role of fluid-phase regulators of complement is to inhibit excessive complement activation and maintain homeostasis in blood. By binding to and inactivating complement components on cell surfaces, they can also protect autologous cells from complement-mediated cytotoxicity and phagocytosis. In this study, we wanted to find out whether C4b-binding protein (C4bp), a fluid-phase regulator of the classical complement pathway, could directly bind to cell surfaces in a functionally active form. After screening several malignant cell lines, we observed that the ovarian adenocarcinoma cell lines SK-OV-3, Caov-3, and SW626 were capable of binding C4bp. Binding tests with recombinant deletion mutants suggested that the primary binding site on C4bp is located on the alpha-chain complement control protein 4 domain. Functional tests showed that tumor cell-bound C4bp retained its cofactor activity for factor I-mediated inactivation of C4b, thus increasing the control of classical complement pathway activation on the surfaces of these cells. These results demonstrate a novel mechanism of complement regulation on cell surfaces, particularly on those of malignant ovarian tumor cells.  (+info)

Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis. (7/80)

Human C4b-binding protein (C4bp) facilitates the factor I-mediated proteolytic cleavage of the active forms of complement effectors C3b and C4b into their inactive forms. C4bp comprises a disulfide-linked heptamer of alpha-chains with complement (C) regulatory activity and a beta-chain. Each alpha-chain contains 8 short consensus repeat (SCR) domains. Using SCR-deletion mutants of recombinant multimeric C4bp, we identified the domains responsible for the C3b/C4b-binding and C3b/C4b-inactivating cofactor activity. The C4bp mutant with deletion of SCR2 lost the C4b-binding ability, as judged on C3b/C4b-Sepharose binding assaying and ELISA. In contrast, the essential domains for C3b-binding extended more to the C-terminus, exceeding SCR4. Using fluid phase cofactor assaying and deletion mutants of C4bp, SCR2 and 3 were found to be indispensable for C4b cleavage by factor I, and SCR1 contributed to full expression of the factor I-mediated C4b cleaving activity. On the other hand, SCR1, 2, 3, 4, and 5 participated in the factor I-cofactor activity for C3b cleavage, and SCR2, 3, and 4 were absolutely required for C3b inactivation. Thus, different sets of SCRs participate in C3b and C4b inactivation, and the domain repertoire supporting C3b cofactor activity is broader than that supporting C4b inactivation by C4bp and factor I. Furthermore, the domains participating in C3b/C4b binding are not always identical to those responsible for cofactor activity. The necessity of the wide range of SCRs in C3b inactivation compared to C4b inactivation by C4bp and factor I may reflect the physiological properties of C4bp, which is mainly directed to C4b rather than C3b.  (+info)

Human complement factor I does not require cofactors for cleavage of synthetic substrates. (8/80)

Complement factor I (fI) plays a major role in the regulation of the complement system. It circulates in an active form and has very restricted specificity, cleaving only C3b or C4b in the presence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, or C4-binding protein. Using peptide-7-amino-4-methylcoumarin derivatives, we investigated the substrate specificity of fI. There is no previous report of synthetic substrate cleavage by fI, but five substrates were found in this study. A survey of 15 substrates and a range of inhibitors showed that fI has specificity similar to that of thrombin, but with much lower catalytic activity than that of thrombin. fI amidolytic activity has a pH optimum of 8.25, typical of serine proteases and is insensitive to ionic strength. This is in contrast to its proteolytic activity within the fI-C3b-fH reaction, in which the pH optimum for C3b cleavage is <5.5 and the reaction rate is highly dependent on ionic strength. The rate of cleavage of tripeptide 7-amino-4-methylcoumarins by fI is unaffected by the presence of fH or C3(NH(3)). The amidolytic activity is inhibited by the synthetic thrombin inhibitor Z-D-Phe-Pro-methoxypropylboroglycinepinanediol ester, consistent with previous reports, and by benzenesulfonyl fluorides such as Pefabloc SC. Suramin inhibits fI directly at concentration of 1 mM. Within a range of metal ions tested, only Cr(2+) and Fe(3+) were found to inhibit both the proteolytic and amidolytic activity of fI.  (+info)

Complement Factor I (C1) is a protein complex that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. C1 is composed of three subunits: C1q, C1r, and C1s. When a pathogen enters the body, it triggers the activation of the complement system, which leads to the formation of a cascade of proteins that ultimately results in the destruction of the pathogen. C1 is the first protein in this cascade to be activated, and it plays a critical role in identifying and binding to the pathogen. Once C1 binds to the pathogen, it triggers the activation of C1r and C1s, which then cleave and activate other complement proteins, leading to the formation of a membrane attack complex (MAC) that can directly destroy the pathogen. C1 also plays a role in regulating the complement system by inhibiting its activation in the absence of a pathogen. In summary, Complement Factor I (C1) is a protein complex that plays a critical role in the complement system, which helps to defend the body against infections and remove damaged cells. It is the first protein in the complement cascade to be activated and plays a critical role in identifying and binding to pathogens.

Complement C3b is a protein fragment that is generated when the complement system, a part of the immune system, is activated. The complement system is a complex network of proteins that work together to help the body fight off infections and remove damaged or abnormal cells. C3b is produced when the complement protein C3 is cleaved by enzymes in the complement system. C3b plays an important role in the complement system by binding to the surface of pathogens or damaged cells and marking them for destruction by immune cells. It also helps to recruit immune cells to the site of infection or injury and can activate other components of the complement system to enhance the immune response. In the medical field, C3b is often measured as a marker of complement system activation. Abnormal levels of C3b can be associated with a variety of medical conditions, including autoimmune disorders, infections, and certain types of cancer.

Complement Factor H (CFH) is a protein that plays a critical role in the complement system, which is a part of the immune system that helps to defend the body against infections. CFH is a soluble protein that is present in the blood and helps to regulate the activity of the complement system by inhibiting the formation of the membrane attack complex (MAC), which is a group of proteins that can cause damage to cells and tissues. CFH is also involved in the regulation of inflammation and the immune response, and it has been implicated in a number of diseases, including age-related macular degeneration (AMD), a common eye disorder that can lead to vision loss, and atypical hemolytic uremic syndrome (aHUS), a rare and life-threatening disorder that can cause kidney failure and other complications. In addition to its role in the complement system, CFH has also been shown to have anti-inflammatory and anti-apoptotic effects, and it may play a role in the development of other diseases, such as cancer and neurodegenerative disorders.

Complement Factor B (CFB) is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. CFB is a soluble protein that is produced by the liver and circulates in the bloodstream. In the complement system, CFB is involved in the activation of the alternative pathway, which is one of three pathways that can activate the complement system. The alternative pathway is activated when antibodies bind to foreign substances on the surface of cells, and CFB helps to amplify the immune response by promoting the formation of a complex that leads to the activation of other complement proteins. Deficiencies in CFB can lead to a condition called complement factor B deficiency, which can result in recurrent infections and other immune system disorders.

Complement Factor D (CFD) is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. CFD is also known as complement factor Bb or membrane attack complex (MAC) convertase. CFD is synthesized in the liver and circulates in the blood as an inactive form. When it encounters a pathogen or damaged cell, it is activated by proteolytic cleavage, which generates two active fragments: C3 convertase and C5 convertase. These convertases cleave other complement proteins, leading to the formation of the membrane attack complex (MAC), which can directly lyse the pathogen or damaged cell. In addition to its role in the complement system, CFD has also been implicated in the development of various diseases, including age-related macular degeneration, atherosclerosis, and systemic lupus erythematosus. Therefore, CFD is an important target for the development of new therapies for these diseases.

Factor I deficiency in turn leads to low levels of complement component 3 (C3), factor B, factor H and properdin in blood, due ... Complement factor I (factor I) is a protein of the complement system, first isolated in 1966 in guinea pig serum, that ... Loss of function mutations in the Complement Factor I gene lead to low levels of factor I which results in increased complement ... Complement factor I, also known as C3b/C4b inactivator, is a protein that in humans is encoded by the CFI gene. ...
... is a protein that in humans is encoded by the CFB gene. This gene encodes complement factor B, a component ... CFB complement factor B". Ambrus JL, Peters MG, Fauci AS, Brown EJ (March 1990). "The Ba fragment of complement factor B ... Christie DL, Gagnon J (January 1983). "Amino acid sequence of the Bb fragment from complement Factor B. Sequence of the major ... Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the ...
"The role of complement factor C3 in lipid metabolism". Molecular Immunology. 15th European Meeting on Complement in Human ... 12th European Meeting on Complement in Human Disease12th European Meeting on CHD12th European Meeting on Complement in Human ... that allows it to bind to a plasma protein called Factor B. This complex is then cleaved by Factor D, a serine protease, to ... Factor I, a serine protease activated by cofactors, can cleave and C3b and C4b, thus preventing convertase formation. C3 ...
Activated C3 can then interact with factor B. Factor B is then activated by factor D, to form Bb. The resultant complex, C3bBb ... "Interactions between human complement components factor H, factor I and C3b". The Biochemical Journal. 326 (2): 553-61. doi: ... Complement component 3 has been shown to interact with Factor H. Deficiencies in C3 lead to genetic infections, usually fatal ... Factor I is the protease cleaves C3b but requires a cofactor (e.g Factor H, CR1, MCP or C4BP) for activity. Several ...
This gene encodes the basic form of complement factor 4, part of the classical activation pathway. The protein is expressed as ... Complement component 4 Complement component 4A HLA A1-B8-DR3-DQ2 haplotype Complement system Complement deficiency ... Aoki H, Takizawa F, Tsuji S, Nagasawa S (Jul 2000). "Elongation factor-1alpha as a homologous complement activator of Jurkat ... Complement component 4B (Chido blood group) is a kind of the Complement component 4 protein that in humans is encoded by the ...
Decay Accelerating Factor, DAF (CD55) Protectin (CD59) Complement C3b/C4b Receptor 1, CR1 (CD35) Complement Regulator of the ... Complement control protein are proteins that interact with components of the complement system. The complement system is ... Complement proteins protect against malignant cells- both by direct complement attack and through initiation of Complement- ... factor H competes with factor B to bind C3b; if it manages to bind, then the convertase is not formed. Factor H can bind C3b ...
PSAP Complement component 4, partial deficiency of; 120790; C1NH Complement factor H deficiency; 609814; HF1 Complement factor ... GLA Factor V and factor VIII, combined deficiency of; 227300; MCFD2 Factor V deficiency; 227400; F5 Factor XI deficiency, ... F11 Factor XII deficiency; 234000; F12 Factor XIIIA deficiency; 613225; F13A1 Factor XIIIB deficiency; 613235; F13B Failure of ... LCAT Fletcher factor deficiency; 612423; KLKB1 Focal cortical dysplasia, Taylor balloon cell type; 607341; TSC1 Focal dermal ...
... complement subgroups factor a group into smaller pieces. As previously mentioned, complements need not exist. A p-complement is ... A Frobenius complement is a special type of complement in a Frobenius group. A complemented group is one where every subgroup ... if K is a complement of H, then H is a complement of K. Neither H nor K need be a normal subgroup of G. Complements need not ... That is, H could have two distinct complements K1 and K2 in G. If there are several complements of a normal subgroup, then they ...
"OMIM Entry - * 300383 - COMPLEMENT FACTOR PROPERDIN; CFP". www.omim.org. Retrieved 2022-03-24. editor., Leung, Donald Y. M., ... The gene responsible for the production of properdin, Complement Factor Properdin (CFP), lies on the X-chromosome at the ... Properdin deficiency is a rare X-linked disease in which properdin, an important complement factor responsible for the ... Pertaining to complement deficiencies, there is no cure and the treatments for complement deficiencies vary widely. The best ...
Like complement factor H, CFHR5 is able to bind to complement C3. A mutation in CHFR5 was found in patients with the disease ... "Entrez Gene: CFHR5 complement factor H-related 5". McRae JL, Duthy TG, Griggs KM, et al. (2005). "Human factor H-related ... 2006). "Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with ... Complement factor H-related protein 5 is a protein that in humans is encoded by the CFHR5 gene. CFHR5 is structurally related ...
Diaz-Guillen MA, Rodriguez de Cordoba S, Heine-Suner D (Jul 1999). "A radiation hybrid map of complement factor H and factor H- ... CFHR4 complement factor H-related 4". Hageman GS, Hancox LS, Taiber AJ, et al. (2007). "Extended Haplotypes in the Complement ... Complement factor H-related protein 4 is a protein that in humans is encoded by the CFHR4 gene. GRCh38: Ensembl release 89: ... 2000). "Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and ...
Complement factor H-related protein 2) at the PDBe-KB. Zipfel PF, Skerka C (1994). "Complement factor H and related proteins: ... Díaz-Guillén MA, Rodríguez de Córdoba S, Heine-Suñer D (1999). "A radiation hybrid map of complement factor H and factor H- ... "Two additional human serum proteins structurally related to complement factor H. Evidence for a family of factor H-related ... Complement factor H-related protein 2 is a protein that in humans is encoded by the CFHR2 gene. GRCh38: Ensembl release 89: ...
"Cellular adhesion mediated by factor J, a complement inhibitor. Evidence for nucleolin involvement". The Journal of Biological ... Nucleolin is also able to act as a transcriptional coactivator with Chicken Ovalbumin Upstream Promoter Transcription Factor II ...
... is produced when complement factor I cleaves C3b. Complement receptors on white blood cells are able to bind iC3b, so iC3b ... thus preventing amplification of the complement cascade through the alternative pathway. Complement factor I can further cleave ... iC3b is a protein fragment that is part of the complement system, a component of the vertebrate immune system. ... v t e (Complement system, All stub articles, Biochemistry stubs). ...
These SNPs were located in the gene encoding complement factor H, which was an unexpected finding in the research of ARMD. The ... April 2005). "Complement factor H polymorphism in age-related macular degeneration". Science. 308 (5720): 385-9. Bibcode: ... "Complement factor H variant increases the risk of age-related macular degeneration". Science. 308 (5720): 419-21. Bibcode: ... It has been identified different variants associated with transcription factor coding-genes, such as TBX3 and TBX5, NKX2-5 o ...
Wu LC, Morley BJ, Campbell RD (Jan 1987). "Cell-specific expression of the human complement protein factor B gene: evidence for ... the body signals the Complement system and the Complement component 2 protein attaches to Complement system 4 resulting in an ... It is also important to note that Complement component 2 deficiency can be caused by genetic and environmental factors. In ... Gagnon J (Sep 1984). "Structure and activation of complement components C2 and factor B". Philosophical Transactions of the ...
It can also be seen in systemic lupus erythematosus as a result of increased usage of complement factors due to the pathology ... The CH50 is testing the classical complement pathway in an individual thus requiring functioning C1-C9 factors. If an ... Total complement activity (TCA) refers to a series of tests that determine the functioning of the complement system in an ... One can interpret the CH50 value along with the individual's complement factor values to help determine the etiology. For ...
Complement factors are decreased in rheumatoid arthritis and lupus arthritis. Microscopic analysis of synovial fluid is ... Jay, GD; Britt, DE; Cha, CJ (March 2000). "Lubricin is a product of megakaryocyte stimulating factor gene expression by human ...
Markusen, James R. (May 1, 1983). "Factor movements and commodity trade as complements". Journal of International Economics. 14 ... Markusen, James R.; Venables, Anthony J. (November 1, 2007). "Interacting factor endowments and trade costs: A multi-country, ... Markusen's international trade and economics research has contributed to the identification of factors that influence trade ... Markusen's regional economics research has investigated how factors such as infrastructure and education, impact economic ...
Calippe, Bertrand; Guillonneau, Xavier; Sennlaub, Florian (March 2014). "Complement factor H and related proteins in age- ... A SNP in the F5 gene causes Factor V Leiden thrombophilia. rs3091244 is an example of a triallelic SNP in the CRP gene on human ... Other factors, like genetic recombination and mutation rate, can also determine SNP density. SNP density can be predicted by ... LD can be affected by two parameters (among other factors, such as population stratification): 1) The distance between the SNPs ...
Malhotra R, Ward M, Sim RB, Bird MI (July 1999). "Identification of human complement Factor H as a ligand for L-selectin". The ... The embryo secretes human chorionic gonadotropin (hCG), which downregulates anti-adhesion factor, MUC-1, located on the uterine ... Human sell consists of 10 exons and its transcription factor is FOXO 1, on the other hand the mouse sell gene is composed of 9 ... an adjacent epidermal growth factor-like domain, two to the consensus repeat units homologous to those found in C3/C4-binding ...
It is the first drug that selectively inhibits factor B, the active component of the complement's C3 and C5 convertases. In ... April 2019). "Small-molecule factor B inhibitor for the treatment of complement-mediated diseases". Proceedings of the National ... Iptacopan is also investigated as a drug in other complement-mediated diseases, like age-related macular degeneration and some ...
April 2005). "Complement factor H variant increases the risk of age-related macular degeneration". Science. 308 (5720): 419-21 ... Some of the factors that should be considered are the level of efficacy of various genetic tests in the general population, ... Combining molecular scale information with macro-scale clinical data, such as patients' tumor type and other risk factors, ... 2 July 2015). "Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular ...
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases. FDA has granted Fast Track designation ...
In the meantime, notebooks and small form factor desktop computers complement the range. The names of the devices borrow from ... Complementing Tuxedo OS, the company is working on tools to control hardware functions and improve usability. Licensed under ...
Opsonins include Mfge8, Gas6, Protein S, antibodies and complement factors C1q and C3b. Phagoptosis has multiple functions ... Pathogenic cells such as bacteria can be opsonised by antibodies or complement factors, enabling their phagocytosis and ...
1989). "20 KDa homologous restriction factor of complement resembles T cell activating protein". Biochem. Biophys. Res. Commun ... When complement activation leads to deposition of C5b678 on host cells, CD59 can prevent C9 from polymerizing and forming the ... Ninomiya H, Sims PJ (1992). "The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain ... 1992). "Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 ...
... factor H, factor HR1 or HR3, membrane cofactor protein, factor I, factor B, complement C3, and thrombomodulin). This results in ... The complement system activation may be due to mutations in the complement regulatory proteins (factor H, factor I, or membrane ... of complement can result from production of anti-factor H autoantibodies or from genetic mutations in any of several complement ... "Platelet-associated complement factor H in healthy persons and patients with atypical HUS". Blood. 114 (20): 4538-4545. doi: ...
Lee FJ, Moss J, Vaughan M (1992). "Human and Giardia ADP-ribosylation factors (ARFs) complement ARF function in Saccharomyces ... ADP-ribosylation factor 5 is a protein that in humans is encoded by the ARF5 gene. ADP-ribosylation factor 5 (ARF5) is a member ... Shin, O H; Exton J H (August 2001). "Differential binding of arfaptin 2/POR1 to ADP-ribosylation factors and Rac1". Biochem. ... Tsuchiya M, Price SR, Tsai SC, Moss J, Vaughan M (March 1991). "Molecular identification of ADP-ribosylation factor mRNAs and ...
"Entrez Gene: CFHR3 complement factor H-related 3". Zipfel PF, Skerka C (1994). "Complement factor H and related proteins: an ... Diaz-Guillen MA, Rodriguez de Cordoba S, Heine-Suner D (Jul 1999). "A radiation hybrid map of complement factor H and factor H- ... Complement factor H-related protein 3 is a protein that in humans is encoded by the CFHR3 gene. GRCh38: Ensembl release 89: ... 2000). "Complement factor H: sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes ...
Factor I deficiency in turn leads to low levels of complement component 3 (C3), factor B, factor H and properdin in blood, due ... Complement factor I (factor I) is a protein of the complement system, first isolated in 1966 in guinea pig serum, that ... Loss of function mutations in the Complement Factor I gene lead to low levels of factor I which results in increased complement ... Complement factor I, also known as C3b/C4b inactivator, is a protein that in humans is encoded by the CFI gene. ...
Complement factor I deficiency is a disorder that affects the immune system. Explore symptoms, inheritance, genetics of this ... or absent complement factor I. The lack (deficiency) of functional complement factor I protein allows uncontrolled activation ... medlineplus.gov/genetics/condition/complement-factor-i-deficiency/ Complement factor I deficiency. ... Complement factor I and several related proteins protect healthy cells by preventing activation of the complement system when ...
Complement factor H. The complement system is a crucial component of the innate immunity against microbial infection. ... Complement factor H, a 155 kDaplasma glycoprotein, is an essential regulatory protein that plays a critical role in the ... Complement factor H has revealed an association with two different renal diseases, glomerulonephri-tisand atypical hemolytic ... Factor H binds to C3b, accelerates the decay of the alternative pathway C3-convertase and acts as a cofactor for the factor ...
... complement-mediated... (More). Complement factor B (FB) mutant variants are associated with excessive complement activation in ... atypical hemolytic uremic syndrome, C3 glomerulopathy, complement, danicopan, factor B, factor D. in Frontiers in Immunology. ... Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome ... Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as ...
title = "Complement C4 Deficiency - A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently ... T1 - Complement C4 Deficiency - A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently ... Complement C4 Deficiency - A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently ... Complement C4 Deficiency - A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently ...
Events / Evening Meeting / Insights from Reliability-Based Design to Complement Load and Resistance Factor Design Approach ... Insights from Reliability-Based Design to Complement Load and Resistance Factor Design Approach. ... "Insights from Reliability-Based Design to Complement Load and Resistance Factor Design Approach," by B.K. Low in the November ...
Dive into the research topics of Functional anatomy of complement Factor H. Together they form a unique fingerprint. ...
... the complement system reacts promptly to threat (AP). Protective membrane-bound and soluble r.. ... Complement Factor H: Function and Dysfunction Due to the constant monitoring of its alternate channel, the complement system ... Pathogenic microorganisms, on the other hand, frequently resist complement assault and so escape destruction. Complement factor ... Binding sites, especially for complement receptor (CR3), malondialdehyde (MDA)-modified proteins, and apolipoprotein E (apoE), ...
Variation registry for Complement factor I deficiency Select database by name. ADAbase. AICDAbase. AIREbase. AK2base. AP3B1base ...
Complement receptor 1 (CR1) has factor H-like activity, permitting factor I to cleave C3b. Membrane cofactor protein also has ... Ehrlich and Morgan termed this factor complement. The complement system as understood today is a multimolecular system composed ... Factor H competes with factor B for binding to C3b and displaces Bb from C3bBb. It accelerates the inactivation of C3b by ... Here, C3b binds to factor B that is cleaved by factor D to Bb. C3bBb complex then acts as the C3 convertase and generates more ...
Complement C3 nephritic factor. Category. Immunology Test background. A proportion of patients with membranoproliferative ...
... complement factor H [CFH], C4b binding protein, and complement factor I [CFI]) [37, 38]. Defective regulation of the complement ... 4. PE and Complement Factors. The complement system, composed of over 30 proteins that act in concert to protect the host ... 2. Angiogenic Factors and PE. Angiogenic factors and their receptors are important regulators of placental vascular development ... A. Sambola, J. Osende, J. Hathcock et al., "Role of risk factors in the modulation of tissue factor activity and blood ...
How endothelial cells protect themselves from complement by expressing decay-accelerating factor (DAF). *Frances Williams1 ... Williams, F. How endothelial cells protect themselves from complement by expressing decay-accelerating factor (DAF). Arthritis ... How endothelial cells protect themselves from complement by expressing decay-accelerating factor (DAF) ... To test the hypothesis that inflammatory cytokines and complement(C) MACs play a role in the expression of DAF, CD59 and MCP, ...
... recognizes human complement factor H which exists in 2 forms. The most common form, of 150 kDa, and the les… ... strong,Mouse anti Human Complement Factor H antibody, clone 028B-244.2.10X (10-10),/strong, ... Mouse anti Human Complement Factor H antibody, clone 028B-244.2.10X (10-10) recognizes human complement factor H which exists ... Complement factor H functions as a cofactor in the inactivation of C3b by factor I. It makes C3b susceptible to cleavage by ...
We now show that complement factor H-related protein 1 (FHR-1) and factor H-like protein 1 (FHL-1), proteins of the FH protein ... Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.. Poolpol K, Orth-Höller D, Speth C, ... Stx2 was shown to activate complement via the alternative pathway, to bind factor H (FH) at short consensus repeats (SCRs) 6-8 ... Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58(1), 77-84. ...
Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors. ... Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors. / ... Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors. ... Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors. ...
Primary: complement. Persistent complement, properdin, or Factor B deficiency. None. Pneumococcal. Meningococcal. Hib (children ... Persons with functional or anatomic asplenia (including sickle cell disease), HIV infection and persistent complement component ... Persons with functional or anatomic asplenia (including sickle cell disease) and persistent complement component deficiency ( ... Other immunosuppressive medications include human immune mediators like interleukins and colony-stimulating factors, immune ...
... transforming growth factor-beta1, tumor necrosis factor-alpha, or interferon-gamma. C3 and factor B proteins were measured in ... In skin the keratinocyte is the major cell type, it is known to produce two soluble complement components, C3 and factor B. In ... Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. ... Tumor necrosis factor-alpha induced production of C3 and interferon-gamma induced production of factor B were inhibited by ...
CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. ... CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. ... CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. ...
Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a ... Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a ... Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a ... Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a ...
Low complement factor H (i.e., ,70%). 3/69 (4.3). Low complement factor I (i.e., ,70%). 1/69 (1.4). ... Frémeaux-Bacchi V, Sellier-Leclerc A-L, Vieira-Martins P, Limou S, Kwon T, Lahoche A, et al. Complement gene variants and Shiga ... Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, et al. Risk factors for the hemolytic uremic syndrome in ... characterization of isolates and identification of risk factors for haemolytic uremic syndrome. BMC Infect Dis. 2015;15:324. ...
... complement factor D.. Proteomic Fingerprint of HDL from ESRD Patients. We then grouped the MS-identified proteins (Table 2) and ... and complement factor D (Table 2). Importantly, we confirmed our results by performing MS of HDL from an independent cohort of ... 7. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease ... 9 Several factors, including inflammation, oxidative stress, and dyslipidemia, are considered decisive for the progression of ...
PspC is a similar protein to PspA that is capable of interacting with the complement through C3 and Factor H [25,38,39]. PspC ... Adhesin, inhibits activation of complement binding factor H. [24,25]. PcpA. Surface Protein. Adhesin, Choline binding protein. ... Cytotoxic, TLR4 agonist, complement activator. [24,25]. PspA. Surface Protein. Inhibits the activation of the complement, binds ... complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor ...
Complement factor (6) Corticotropin-Releasing Factor (CRF) (3) C-Peptide (6) Cyclin-dependent kinase (3) ...
... such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement ... Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1. 106 (12): ... Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal ... including the decay-accelerating factor (DAF), or CD55 [9] ; homologous restriction factor (HRF), or C8 binding protein; and ...
... in the complement factor H (CFH) gene, rs 11200638-SNP in the high temperature requirement A-1 (HTRA1) gene, two SNPs (rs699947 ... Eight phenotypic factors and ten genotypic factors for three single nucleotide polymorphisms (SNPs; rs800292, rs1061170, ... Therefore, this variant may be used as a prognostic factor to estimate the PDT response with significant predictive power. ... Keywords: age-related macular degeneration, photodynamic therapy, phenotypic and genotypic factors, high temperature ...
Complement Factor H Antibody [Unconjugated]. AF4779. Goat Polyclonal Species Human. Applications WB, IHC ... The Interaction With Host Pathway complements our catalog of research reagents including antibodies and ELISA kits against TNF ...
Association of complement factor H Y402H gene polymorphism with Alzheimers disease. Madeleine Zetterberg, Sara Landgren, Malin ... Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Maria Bjerke, Erik Portelius, Lennart ... Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis ... Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia ...
Ultra-rare complement factor 8 coding variants in families with age-related macular degeneration. Iscience. PMID: 37153444 ... A CEP290 C-Terminal Domain Complements the Mutant CEP290 of Rd16 Mice In Trans and Rescues Retinal Degeneration. Cell Reports. ... Protein kinase CK2 modulates the activity of Maf-family bZIP transcription factor NRL in rod photoreceptors of mammalian retina ... Protein kinase CK2 modulates the activity of Maf-family bZIP transcription factor NRL in rod photoreceptors of mammalian retina ...
Ramirez, G. et al. Trypanosoma cruzi calreticulin: A novel virulence factor that binds complement c1 on the parasite surface ... Met can reduce the production of different pro-inflammatory factors and induce anti-inflammatory factors, regulating the ... induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J. Biol. Chem. 289 ... such as the excessive production of pro-inflammatory factors23. In septic patients, the maximum level of CS activity in ...
  • Complement factor I and several related proteins protect healthy cells by preventing activation of the complement system when it is not needed. (medlineplus.gov)
  • Binding sites, especially for complement receptor (CR3), malondialdehyde (MDA)-modified proteins, and apolipoprotein E (apoE), are dispersed throughout its 20 CCP modules (CCPs), also known as short consensus repeats, to facilitate additional 'non-canonical' FH activities. (imedpub.com)
  • The complement system as understood today is a multimolecular system composed of more than 32 proteins and consisting of serum proteins, serosal proteins, and cell membrane receptors that bind to complement fragments. (medscape.com)
  • The complement system consists of 7 serum and 9 membrane regulatory proteins, 1 serosal regulatory protein, and 8 cell membrane receptors that bind complement fragments. (medscape.com)
  • Cell surface proteins have evolved which prevent EC damage by the cytotoxic defence system, decay-accelerating factor (DAF), protectin (CD59) and membrane cofactor protein (MCP). (biomedcentral.com)
  • We now show that complement factor H-related protein 1 (FHR-1) and factor H-like protein 1 (FHL-1), proteins of the FH protein family that show amino acid sequence and regulatory function similarities with FH, also bind to Stx2. (leibniz-hki.de)
  • C3 and factor B proteins were measured in culture supernatant by enzyme-linked immunosorbent assay and C3 and factor B transcripts in harvested cells by reverse transcriptase - polymerase chain reaction . (bvsalud.org)
  • Cytokine induced upregulation of C3 and factor B proteins was always associated with the upregulation of levels of C3 and factor B mRNA . (bvsalud.org)
  • thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. (medscape.com)
  • How do distinct transcriptional regulatory proteins coordinate their job with extrinsic factors and the microenvironment? (nih.gov)
  • The active ingredient comprises plasma proteins such as albumin , immunoglobulins, other globulins, coagulation factors, complement proteins and protease inhibitors. (rxlist.com)
  • Genes that encode the proteins of complement components or their isotypes are distributed throughout different chromosomes, with 19 genes comprising 3 significant complement gene clusters in the human genome. (medscape.com)
  • The important components of this system are various cell membrane-associated proteins such as complement receptor 1 (CR1), complement receptor 2 (CR2), and decay accelerating factor (DAF). (medscape.com)
  • for example, the proteins factor H and factor I inhibit the formation of the enzyme C3 convertase of the alternative pathway. (medscape.com)
  • Factor I deficiency in turn leads to low levels of complement component 3 (C3), factor B, factor H and properdin in blood, due to unregulated activation of C3 convertase, and to low levels of IgG, due to loss of iC3b and C3dg production. (wikipedia.org)
  • Complement factor I deficiency is a disorder that affects the immune system. (medlineplus.gov)
  • Some people with complement factor I deficiency have a kidney disorder called glomerulonephritis with isolated C3 deposits. (medlineplus.gov)
  • Complement factor I deficiency can also be associated with autoimmune disorders such as rheumatoid arthritis or systemic lupus erythematosus (SLE). (medlineplus.gov)
  • Complement factor I deficiency is caused by mutations in the CFI gene. (medlineplus.gov)
  • Mutations in the CFI gene that cause complement factor I deficiency result in abnormal, nonfunctional, or absent complement factor I. The lack (deficiency) of functional complement factor I protein allows uncontrolled activation of the complement system. (medlineplus.gov)
  • Baracho GV, Nudelman V, Isaac L. Molecular characterization of homozygous hereditary factor I deficiency. (medlineplus.gov)
  • Grumach AS, Leitao MF, Arruk VG, Kirschfink M, Condino-Neto A. Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family. (medlineplus.gov)
  • Ponce-Castro IM, Gonzalez-Rubio C, Delgado-Cervino EM, Abarrategui-Garrido C, Fontan G, Sanchez-Corral P, Lopez-Trascasa M. Molecular characterization of Complement Factor I deficiency in two Spanish families. (medlineplus.gov)
  • Cases of complement deficiency have helped defined the role of complement in host defense. (medscape.com)
  • Factor H binds to C3b, accelerates the decay of the alternative pathway C3-convertase and acts as a cofactor for the factor Imediated proteolyticinac-tivation of C3b. (biovendor.com)
  • Depending on the nature of complement activators, the classic pathway, the alternative pathway, or the more recently discovered lectin pathway is activated predominantly to produce C3 convertase. (medscape.com)
  • Stx2 was shown to activate complement via the alternative pathway, to bind factor H (FH) at short consensus repeats (SCRs) 6-8 and 18-20 and to delay and reduce FH cofactor activity on the cell surface. (leibniz-hki.de)
  • Atypical hemolytic uremic syndrome (aHUS) is a disease associated with dysregulation of the immune complement system, especially of the alternative pathway (AP). (elsevierpure.com)
  • In vitro activation of the alternative pathway of complement by settled grain dust. (cdc.gov)
  • To study the effect of MAC on HMEC expression of DAF, EC monolayers were opsonised with IgG2a anti-endoglin monoclonal antibody, thus optimising complement fixation ability. (biomedcentral.com)
  • Mouse anti Human Complement Factor H antibody, clone 028B-244.2.10X (10-10) recognizes human complement factor H which exists in 2 forms. (bio-rad-antibodies.com)
  • Lectins activate the lectin pathway in a manner similar to the antibody interaction with complement in the classical pathway. (medscape.com)
  • Activation of the complement pathways. (medscape.com)
  • This prevents these components of the classical and of alternative complement pathways from forming a positive feedback loop. (bio-rad-antibodies.com)
  • We are now focused on delineating the transcription factors and signaling pathways that are responsible for generating photoreceptors from retinal progenitor cells. (nih.gov)
  • The complement cascade consists of 3 separate pathways that converge in a final common pathway. (medscape.com)
  • Complement pathways and deficiencies. (medscape.com)
  • Conventional protease inhibitors do not completely inactivate Factor I but they can do so if the enzyme is pre-incubated with its substrate: this supports the proposed rearrangement of the molecule upon binding to the substrate. (wikipedia.org)
  • In conclusion, multiple interactions of key complement inhibitors FH, FHR-1 and FHL-1 with Stx2 corroborate our hypothesis of a direct role of complement in EHEC-associated HUS. (leibniz-hki.de)
  • The factor I heavy chain has four domains: an FI membrane attack complex (FIMAC) domain, CD5 domain, and low density lipoprotein receptor 1 and 2 (LDLr1 and LDLr2) domains. (wikipedia.org)
  • the heavy chain plays an inhibitory role in maintaining the enzyme inactive until it meets the complex formed by the substrate (either C3b or C4b) and a cofactor protein (Factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein). (wikipedia.org)
  • Similarly, sEng is a truncated form of receptor for two subtypes of transforming growth factor beta (TGF β ) specifically, TGF β 1 and TGF β 2 which are highly expressed by vascular endothelial cells and syncytiotrophoblasts. (hindawi.com)
  • Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN). (lu.se)
  • Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a cofactor for mediating C3 inactivation by complement factor I. However, anomalies related to CFH are known to cause excessive complement activation and cytotoxicity. (elsevierpure.com)
  • Complement factor I (factor I) is a protein of the complement system, first isolated in 1966 in guinea pig serum, that regulates complement activation by cleaving cell-bound or fluid phase C3b and C4b. (wikipedia.org)
  • An intricate system regulates complement activity. (medscape.com)
  • Loss of function mutations in the Complement Factor I gene lead to low levels of factor I which results in increased complement activity. (wikipedia.org)
  • These results suggest that FD inhibition can effectively block complement overactivation induced by FB gain-of-function mutations. (lu.se)
  • Complement factor I, also known as C3b/C4b inactivator, is a protein that in humans is encoded by the CFI gene. (wikipedia.org)
  • Then, factor I is cleaved by furin to yield the mature factor I protein, which is a disulfide-linked dimer of heavy chain (residues 19-335, 51 kDalton) and light chain (residues 340-583, 37 kDalton). (wikipedia.org)
  • This gene provides instructions for making a protein called complement factor I. This protein helps regulate a part of the body's immune response known as the complement system . (medlineplus.gov)
  • The unregulated activity of the complement system decreases blood levels of another complement protein called C3, reducing the immune system's ability to fight infections. (medlineplus.gov)
  • Complement factor H, a 155 kDaplasma glycoprotein, is an essential regulatory protein that plays a critical role in the homeostasis of the complement system in plasma and in the protection of bystander host cells and tissues from damage by complement activation. (biovendor.com)
  • In addition, factor H has multiple physiological activities acts as an extracellularmatrix component, binds to cellular receptors of the integrintype, and interacts with a wide selection of ligands, such as the C-reactive protein, thrombospondin, bone sialoprotein, osteopontin, and heparin. (biovendor.com)
  • Complement factor H is a soluble AP suppressor that recognizes self-surfaces on autologous surfaces, either directly via particular glycosaminoglycan and sialic acid or indirectly via C-reactive protein (CRP), and operates in fluid phase. (imedpub.com)
  • Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. (leibniz-hki.de)
  • Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. (leibniz-hki.de)
  • NRL interacts with homeodomain protein CRX and numerous other regulatory factors to control expression of most rod-expressed genes. (nih.gov)
  • These bacteria use the surface protein Usp2 to capture and incapacitate the major complement factor C3. (lu.se)
  • How do endothelial cells (ECs) protect themselves against damage by complement, particularly when they are present at the interface between blood and inflamed tissue? (biomedcentral.com)
  • DAF prevents the formation and accelerates the decay of complement 3 (C3) convertases, MCP binds to C3b and C4b promoting their degradation and CD59 inhibits the membrane-attack complex (MAC). (biomedcentral.com)
  • The most widely studied serum markers for PE, to date, are vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). (hindawi.com)
  • Factor H is secreted by the liver into the blood serum. (bio-rad-antibodies.com)
  • Crain, SM, Bornstein, MB & Lennon, VA 1975, ' Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors ', Experimental Neurology , vol. 49, no. 1, pp. 330-335. (elsevierpure.com)
  • Abolition of depression by preheating the sera, and restoration, in some cases,b y addition of fresh (unheated) guinea pig serum (10%) suggested that the effect was complement-dependent (see below). (elsevierpure.com)
  • More direct demonstration of complement-dependence was difficult since many of the sera blocked bioelectric discharges even without addition of guinea pig serum. (elsevierpure.com)
  • CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. (ouhsc.edu)
  • The effects of settled grain dust on the human serum complement cascade were investigated. (cdc.gov)
  • Clinical significance of complement deficiencies. (medlineplus.gov)
  • The dosage of Octaplas for replacement of multiple coagulation factors in patients with acquired deficiencies is 10 to 15 milliliters per kg. (rxlist.com)
  • Deficiencies in the complement cascade can lead to overwhelming infection and sepsis. (medscape.com)
  • Complement deficiencies are said to comprise between 1 and 10% of all primary immunodeficiencies. (medscape.com)
  • [ 3 ] A registry of complement deficiencies has been established as a means to promote joint projects on treatment and prevention of diseases associated with defective complement function. (medscape.com)
  • This article outlines some of the disease states associated with complement deficiencies and their clinical implications. (medscape.com)
  • Deficiencies in complement predispose patients to infection via 2 mechanisms: (1) ineffective opsonization and (2) defects in lytic activity (defects in MAC). (medscape.com)
  • Specific complement deficiencies are also associated with an increased risk of developing autoimmune disease, such as SLE. (medscape.com)
  • It is important in regulating the complement pathway, preventing unnecessary inflammation which can damage the host tissue. (bio-rad-antibodies.com)
  • The complement system plays an important part in host defense and inflammation . (bvsalud.org)
  • 4 , 6 - 9 Several factors, including inflammation, oxidative stress, and dyslipidemia, are considered decisive for the progression of atherosclerosis in ESRD. (lww.com)
  • at the same time, the inflammation promoted by complement activation can result in cellular damage when not kept in check. (medscape.com)
  • Dive into the research topics of 'Functional anatomy of complement Factor H'. Together they form a unique fingerprint. (ed.ac.uk)
  • Some new clinical entities are linked with partial complement defects. (medscape.com)
  • Binding of factor H to C3b increases its inactivation by factor I. Properdin stabilizes it, preventing its inactivation by factors H and I. The alternate pathway does not result in a truly nonspecific activation of complement because it requires specific types of compounds for activation. (medscape.com)
  • Complement factor H functions as a cofactor in the inactivation of C3b by factor I. It makes C3b susceptible to cleavage by factor I, resulting in iC3b. (bio-rad-antibodies.com)
  • Atypical hemolytic uremic syndrome is caused by complement overactivation. (wikipedia.org)
  • We showed that one common strategy is to bind complement inhibitor C4BP, which leads to decreased opsonisation of bacteria with C3b impairing phagocytosis and allowing bacterial survival. (lu.se)
  • Aliquots were analyzed for factor-B conversion and hemolytic activity. (cdc.gov)
  • The complement system is a crucial component of the innate immunity against microbial infection. (biovendor.com)
  • Due to the constant monitoring of its alternate channel, the complement system reacts promptly to threat (AP). (imedpub.com)
  • The complement system functions as an interactive sequence, with one reaction leading to another in the form of a cascade. (medscape.com)
  • The complement system has recently been found to be involved in the pathogenesis of EHEC-associated HUS. (leibniz-hki.de)
  • The complement system is part of the innate immune system. (medscape.com)
  • The complement system plays an important part in defense against pyogenic organisms. (medscape.com)
  • In addition to playing an important role in host defense against infection, the complement system is a mediator in both the pathogenesis and prevention of immune complex diseases, such as systemic lupus erythematosus (SLE). (medscape.com)
  • These findings underscore the duality of the complement system. (medscape.com)
  • Knowledge about the complement system is expanding. (medscape.com)
  • Although the complement system is part of the body's innate, relatively nonspecific defense against pathogens, its role is hardly primitive or easily understood. (medscape.com)
  • The gene for Factor I in humans is located on chromosome 4. (wikipedia.org)
  • rs800292, rs1061170, rs1410996) in the complement factor H ( CFH ) gene, rs 11200638-SNP in the high temperature requirement A-1 ( HTRA1 ) gene, two SNPs (rs699947, rs2010963) in the vascular endothelial growth factor ( VEGF ) gene, and four SNPs (rs12948385, rs12150053, rs9913583, rs1136287) in the pigment epithelium-derived factor ( PEDF ) gene were evaluated. (dovepress.com)
  • The term "nocturnal" refers to the belief that hemolysis is triggered by acidosis during sleep and activates complement to hemolyze an unprotected and abnormal RBC membrane. (medscape.com)
  • This in turn results in an exponential production of multiple factors such as cytokines and growth factors leading to the clinical manifestations of PE [ 11 ]. (hindawi.com)
  • To test the hypothesis that inflammatory cytokines and complement(C) MACs play a role in the expression of DAF, CD59 and MCP, and to investigate the intracellular signalling pathway involved in DAF expression. (biomedcentral.com)
  • Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. (bvsalud.org)
  • In skin the keratinocyte is the major cell type, it is known to produce two soluble complement components, C3 and factor B . In this study we investigated the regulation of synthesis of these components in foreskin keratinocytes by cytokines . (bvsalud.org)
  • In conclusion, synthesis of C3 and factor B in keratinocytes is regulated by some cytokines , known to be produced by inflammatory cells and keratinocytes . (bvsalud.org)
  • Here, C3b binds to factor B that is cleaved by factor D to Bb. (medscape.com)
  • As a first line of defense against pathogens and a mediator between innate and adaptive immunity, complement is a particular focus of evasion strategies developed by pathogens. (lu.se)
  • Factor I is a glycoprotein heterodimer consisting of a disulfide linked heavy chain and light chain. (wikipedia.org)
  • Mutagenesis was performed to study the effect of factor D (FD) inhibition on C3 convertase-induced FB cleavage, complement-mediated. (lu.se)
  • In the first phase, a series of specific interactions leads to formation of intrinsic complement proteinase, termed C3 convertase. (medscape.com)
  • Factor H also inhibits the formation of the C3bBb complex (C3 convertase) and increases the rate of dissociation of both C3 convertase and the (C3b)NBB complex (C5 convertase). (bio-rad-antibodies.com)
  • Complement factor H has revealed an association with two different renal diseases, glomerulonephri-tisand atypical hemolytic uremicsyndrome (aHUS). (biovendor.com)
  • Patients with aHUS are currently treated with eculizumab while there is no specific treatment for other complement-mediated renal diseases. (lu.se)
  • In addition to the following diseases, low factor I is associated with recurrent bacterial infections in children. (wikipedia.org)
  • How the immune response can activate the cascade process is still unknown but it is proposed to act in synergy with additional exacerbating factors such as predisposing maternal and ambient factors [ 12 ]. (hindawi.com)
  • New studies point to the complex interplay between the complement cascade and adaptive immune response, and complement is also being studied in association with ischemic injury as a target of therapy. (medscape.com)
  • This indicated that, as expected, cytokine -induced enhancement in C3 and factor B levels was due to an increase in synthesis rather than their possible release from intracellular stores. (bvsalud.org)
  • The accumulation of anaphylatoxins (such as C5a) from complement activation might also have a role. (medscape.com)
  • Locally synthesized complement may perform these functions at tissue and organ level. (bvsalud.org)
  • Angiogenic factors and their receptors are important regulators of placental vascular development [ 13 ]. (hindawi.com)
  • We previously discovered that that Maf-family bZIP transcription factor NRL is critical for rod photoreceptor fate and functional differentiation, and that loss of NRL leads to S-cones instead of rods. (nih.gov)
  • Crystal structure the crystal structure of human Factor I has been deposited as PDB: 2XRC. (wikipedia.org)
  • Human keratinocytes were cultured in the presence of supernatant of activated peripheral blood mononuclear cells , interleukin-1alpha , interleukin-2 , interleukin-6 , transforming growth factor-beta1 , tumor necrosis factor-alpha , or interferon-gamma . (bvsalud.org)
  • Another important mechanism by which bacteria resist human complement is the production of proteases that efficiently degrade complement components. (lu.se)
  • Like sFlt1, soluble endoglin (sEng) is an antiangiogenic factor capable of inhibiting capillary tube formation in vitro [ 17 ]. (hindawi.com)
  • Pathogenic microorganisms, on the other hand, frequently resist complement assault and so escape destruction. (imedpub.com)
  • 1 It is a multifactorial disease with several identified genetic and environmental risk factors, including age, smoking, body mass index, hypertension, and others. (dovepress.com)
  • So that suspect case of Ebola disease or suspect case of Ebola disease definition is a person with signs and symptoms compatible with Ebola disease and an epidemiological risk factor within 21 days before the onset of symptoms. (cdc.gov)
  • Dysregulated factor I activity has clinical implications. (wikipedia.org)
  • Complement consumption also was tested in dust treated sera from C4 deficient guinea pigs. (cdc.gov)
  • Complement reductions also were seen in the treated sera from C4 deficient guinea-pigs. (cdc.gov)
  • The Interaction With Host Pathway complements our catalog of research reagents including antibodies and ELISA kits against TNF, IL6, IL2, TLR2, TLR4. (novusbio.com)
  • Treatment is with dietary supplements, intravitreal injection of antivascular endothelial growth factor drugs, laser photocoagulation, photodynamic therapy, and low-vision devices. (msdmanuals.com)
  • This study aimed to demonstrate the phenotypic and genotypic factors associated with photodynamic therapy (PDT) for age-related macular degeneration (AMD). (dovepress.com)